



KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH

(A unit of Kovai Medical Center and Hospital Limited)

Coimbatore, Tamilnadu

**SERIES 8
MARCH 2020**

DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE

Creating the Future



- ❖ *New drugs*
- ❖ *Available drugs with new formulation*

Inside this series

New Drug Approvals by FDA

- 1. Eptinezumab-jjmr**
- 2. Bempedoic acid**
- 3. Amisulpride**
- 4. Bempedoic acid and Ezetimibe**
- 5. Rimegepant**

1. Eptinezumab-jjmr

- **Date of Approval:** February 21, 2020
- **Mechanism of action:** Monoclonal antibody - CGRP antagonist
- **Indication:** Preventive treatment of Migraine in adults
- **Dosage Formulation:** Injection for Intravenous use

2. Bempedoic acid

- **Date of Approval:** February 21, 2020
- **Mechanism of action:** First-in-class, Adenosine triphosphate-citrate lyase inhibitor
- **Indication:** Heterozygous Familial Hypercholesterolemia
- **Dosage Formulation:** Tablet

3. Amisulpride

- **Date of Approval:** February 26, 2020
- **Mechanism of action:** Dopamine antagonist
- **Indication:** Post-Operative Nausea & Vomiting
- **Dosage Formulation:** Injection for Intravenous Infusion

4. Bempedoic acid and Ezetimibe

- **Date of Approval:** February 26, 2020
- **Mechanism of action:** Adenosine triphosphate-citrate lyase inhibitor and a cholesterol absorption inhibitor combination
- **Indication:** Heterozygous Familial Hypercholesterolemia
- **Dosage Formulation:** Tablet

5. Rimegepant

- **Date of Approval:** February 27, 2020
- **Mechanism of action:** Calcitonin gene-related peptide receptor antagonist
- **Indication:** Acute treatment of Migraine
- **Dosage Formulation:** Orally Disintegrating Tablet

COMPILED & EDITED by
Department of Pharmacology
KMCHHSR, Coimbatore, 641014

Kindly Mail Your Suggestions To:
hodpharmacology@kmchihsr.edu.in

Access this series through
KMCHHSR website
www.kmchihsr.edu.in